Staff and Patients at Allied Services Prepare for Stroke Miracle Lap

Staff and patients at Allied Services are busily preparing for the 2022 Stroke Miracle Lap. The walk will take place as part of the Northeast PA Heart Walk on Saturday, May 21, 2022, at PNC Field in Moosic, PA. Allied Services is a proud sponsor of this event, and a member of its leadership team is chairing the 2022 Northeast PA Heart Walk. 

“As stroke rehab specialists, we know what an impact stroke and heart disease can have on individuals and families in the communities we live and work in,” said Jim Brogna, Vice President of Strategic Business Partnership at Allied Services and Chair of the 2022 Northeast PA Heart Walk. “We’re proud to support the American Heart and Stroke Association’s work to raise awareness of and prevent heart attacks and stroke.” 

Following the opening ceremonies at 9:00 a.m., stroke survivors, stroke rehab specialists, family, and community members will take to the field for the Allied Services Stroke Miracle Lap. This is the fourth year of the Stroke Miracle Lap. 

“For us, it’s an opportunity to honor and remember those we have lost to stroke and to celebrate the milestones of stroke survivors,” said Jim Brogna. “Stroke recovery can be a lifelong journey. Allied Services is committed to giving stroke patients access to the latest rehab technology, the best clinicians, and the ongoing support for their continuing recovery.” 

Participants in the walk on May 21 will be wearing their signature blue Stroke Miracle Lap. In readiness for the walk, staff throughout Allied Services took part in a stroke awareness dress-down day on Friday, May 13, wearing the Stroke Miracle Lap shirts. Allied Services doubled the contributions of its employees and will be presenting a donation for $3,300 to the American Stroke Association at the Stroke Miracle Lap on May 21. 

The Allied Services Stroke Miracle Lap is free and open to all ages. You can learn more by calling 570.348.1275 or visiting 

Researchers Find AI Can Predict New Atrial Fibrillation, Stroke Risk

A team of scientists from Geisinger and Tempus have found that artificial intelligence can predict risk of new atrial fibrillation (AF) and AF-related stroke.

Atrial fibrillation is the most common cardiac arrhythmia and is associated with numerous health risks, including stroke and death. The study, published in Circulation, used electrical signals from the heart—measured from a 12-lead electrocardiogram (ECG)—to identify patients who are likely to develop AF, including those at risk for AF-related stroke.

“Each year, over 300 million ECGs are performed in the U.S. to identify cardiac abnormalities within an episode of care. However, these tests cannot generally detect future potential for negative events like atrial fibrillation or stroke,” said Joel Dudley, chief scientific officer at Tempus. “This critical work stems from our major investments in cardiology to generate algorithms that make existing cardiology tests, such as ECGs, smarter and capable of predicting future clinical events. Our goal is to enable clinicians to act earlier in the course of disease.”

To develop their model, the team of data scientists and medical researchers used 1.6 million ECGs from 430,000 patients over 35 years of patient care at Geisinger. These data were used to train a deep neural network—a specialized class of artificial intelligence—to predict, among patients without a previous history of AF, who would develop AF within 12 months. The neural network performance exceeded that of current clinical models for predicting AF risk. Furthermore, 62% of patients without known AF who experienced an AF-related stroke within three years were identified as high risk by the model before the stroke occurred.

“Not only can we now predict who is at risk of developing atrial fibrillation, but this work shows that the high risk prediction precedes many AF-related strokes,” said Brandon Fornwalt, M.D., Ph.D., co-senior author and chair of Geisinger’s Department of Translational Data Science and Informatics. “With that kind of information, we can change the way these patients are screened and treated, potentially preventing such severe outcomes. This is huge for patients.”

Geisinger and Tempus continue to work together to advance precision medicine using practical applications of artificial intelligence. Funding for this project was provided by Geisinger Clinic and Tempus.

Geisinger has an exciting research environment with more than 50 full-time research faculty and more than 30 clinician scientists. Areas of expertise include precision health, genomics, informatics, data science, implementation science, outcomes research, health services research, bioethics and clinical trials.